Share Price, page-10783

Wouldn't that be nice. Based on the previous timings it does seem likely the TH will occur in the first part of Q3, and to date the estimates provided have been very accurate.

As far as I know we have these things slated for Q3.

• Angelman NNZ-2591 readout
• Phelan McDermid end of Phase 2 meeting with FDA (important for subsequent phase 2's including Prader-Willi.
• Acadia's Q2 earnings
• NEU 4C (probably interesting just to see how much cash is at bank - and if costs are stable)

Another good result should for NNZ-2591 should make the claim of a platform drug nearly undeniable. Personally, I'd like to get the Q2 Daybue earnings out of the way. I think the negativity is way overdone and if they don't revise guidance downwards in Q2 it is safe to assume the range we were given at the start of the year will be accurate and I will be happy with that.

The FDA meeting is incredibly important, but probably not a share price catalyst. if the FDA agrees to a protocol change requiring less onerous procedures it will make a big difference to subsequent trials and it will make things a lot clearer for Neuren or a potential acquirer.

As a side note, short Position continued to climb over 3.5m shares now (2.74%) as of June 26th. That is a minimum of a 50% increase to net short sold shares in a single month.